ADC Therapeutics SA
NYSE:ADCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ADC Therapeutics SA
Total Current Assets
ADC Therapeutics SA
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Total Current Assets
$306.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Current Assets
$2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
29%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Current Assets
CHf251.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-4%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Current Assets
CHf223.8m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Current Assets
CHf82.7m
|
CAGR 3-Years
38%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Current Assets
CHf15.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
ADC Therapeutics SA
Glance View
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
See Also
What is ADC Therapeutics SA's Total Current Assets?
Total Current Assets
306.3m
USD
Based on the financial report for Dec 31, 2025, ADC Therapeutics SA's Total Current Assets amounts to 306.3m USD.
What is ADC Therapeutics SA's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-7%
Over the last year, the Total Current Assets growth was 0%. The average annual Total Current Assets growth rates for ADC Therapeutics SA have been -12% over the past three years , -7% over the past five years .
